Home/Filings/4/0001209191-18-017216
4//SEC Filing

McClellan Michael James 4

Accession 0001209191-18-017216

CIK 0000818686other

Filed

Mar 5, 7:00 PM ET

Accepted

Mar 6, 4:16 PM ET

Size

9.1 KB

Accession

0001209191-18-017216

Insider Transaction Report

Form 4
Period: 2018-03-03
McClellan Michael James
EVP, Chief Financial Officer
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2018-03-03+1,04911,377.272 total
  • Tax Payment

    Ordinary Shares

    2018-03-05$19.38/sh455$8,81810,922.272 total
  • Exercise/Conversion

    Restricted Share Units

    2018-03-031,0493,148 total
    Ordinary Shares (1,049 underlying)
Footnotes (3)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • [F3]Restricted share units were granted on March 3, 2017, with 1,049 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,050 vesting on Mach 3, 2021.

Issuer

TEVA PHARMACEUTICAL INDUSTRIES LTD

CIK 0000818686

Entity typeother

Related Parties

1
  • filerCIK 0001721544

Filing Metadata

Form type
4
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 4:16 PM ET
Size
9.1 KB